Share on LinkedInShare on LinkedIn

ARTICLE · 20 DECEMBER 2016

FLH Client Supernus Prevails At CAFC

Following a December 8, 2016 oral argument, the United States Court of Appeals for the Federal Circuit entered a Rule 36 judgment on December 12, 2016...

United StatesIntellectual Property

Following a December 8, 2016 oral argument, the United States Court of Appeals for the Federal Circuit entered a Rule 36 judgment on December 12, 2016 unanimously affirming the District of New Jersey's February 2016 ruling that Actavis Inc. and several of its subsidiaries infringed two patents owned by FLH client Supernus Pharmaceuticals, Inc. by seeking permission from FDA to market a generic version of Oxtellar XR® before the expiration of Supernus's patents. The Federal Circuit's judgment also confirms that Supernus's Oxtellar XR® patents are valid over multiple invalidity grounds argued by Actavis. Oxtellar XR®—Supernus's once-a-day oxcarbazepine tablets used to treat partial seizures in adults and children—is one of two products marketed by Supernus, a Rockville, Maryland-based specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. We are particularly pleased that we could

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from